Under 10% of people eligible to benefit from weight-loss injections such as Wegovy have access to them, caution the global health agency as it publishes its inaugural advice on the therapies.
With in excess of 1,000,000,000 people worldwide now living with obesity, it is advocating for increased and just availability to GLP-1 medication.
Per estimates, more than two billion are projected to be living with obesity by 2030 unless action is taken.
"The latest guidelines recognises that excess weight is a chronic disease that can be managed with thorough and lifelong care," remarked its chief Tedros Adhanom Ghebreyesus.
Significant expense, limited production capacity, and distribution challenges are major obstacles to universal availability to the jabs that can help people shift significant weight, says the body.
Skinny Jab Supply Crisis
Even in the present most optimistic outlook, the supply of GLP-1 therapies would only suffice for about 100 million people – less than 10% of those who need them, as stated by the health organization.
The recommendation calls on governments and firms to widen availability, via strategies such as licensing agreements.
The intellectual property rights on a key compound – the main component of the drug Wegovy – is due to expire in multiple nations in 2026.
How Obesity Jabs Function
The injections imitate a body's own hormone to slow digestion, curb appetite and enhance satiety so users eat less.
Patients typically see weight reduction after several weeks of starting on the weekly injections.
Research points to patients may regain a significant portion after a year of discontinuing the drug, as their usual hunger resume.
Being carrying excess weight elevates your chance for contracting medical conditions, like diabetes, heart disease, brain attack, and some malignancies.
Obesity concerns people in all nations and was responsible for millions of fatalities worldwide in 2024, according to the WHO.
